CapsoVision (CV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 11, 2026, allowing shareholders to vote and ask questions online using a secure control number.
Shareholders will vote on the re-election of three Class I directors and the ratification of the independent auditor for 2026.
Only common stockholders as of April 13, 2026, are eligible to vote; 49,849,728 shares are outstanding.
The company continues to qualify as an emerging growth company, utilizing reduced disclosure requirements.
Voting matters and shareholder proposals
Shareholders will vote on: (1) re-election of three Class I directors (Joanne Imperial, M.D., Wen-Herng King, Michele Harari) for terms expiring in 2029; (2) ratification of Baker Tilly US, LLP as independent auditor for 2026.
Board recommends voting FOR all director nominees and FOR auditor ratification.
Shareholders may submit proposals for the 2027 meeting by December 29, 2026.
Board of directors and corporate governance
The board consists of seven members divided into three staggered classes; majority are independent under Nasdaq rules.
Board committees include Audit and Compensation; no separate Nominating Committee, as independent directors fulfill this role.
Corporate Governance Guidelines and Code of Conduct are in place and regularly reviewed.
Board leadership is separated between the Chair and CEO roles.
Board met 11 times in 2025; committee attendance was high.
Latest events from CapsoVision
- GI diagnostics innovator seeks up to $250M in flexible offerings, highlighting growth and pipeline.CV
Registration filing - Q2 2026 revenue up 10% to $3.6M, but net loss widened and going concern risks remain.CV
Q2 2026 - Directors and auditor ratified; governance and long-term value reaffirmed.CV
AGM 2026 - Q1 2026: $2.8M revenue, 48% margin, $7M net loss, $14M raised, ongoing going concern risk.CV
Q1 2026 - AI-driven GI diagnostics firm registers 2.87M shares for resale after $14M private placement.CV
Registration filing - AI-powered capsule endoscopy drives growth and innovation in noninvasive GI screening.CV
Corporate presentation - 2025 revenue rose 15% to $13.6M, but net loss increased to $25.3M amid higher R&D and public costs.CV
Q4 2025 - AI-driven capsule endoscopy platform expands into major GI markets, backed by strong financing.CV
The 38th Annual Roth Conference - Offering 5.25M shares at $5.00–$5.50 to fund R&D; strong growth but ongoing losses and regulatory risks.CV
Registration Filing